Join
Live feed
·
PRReleasevia Quantisnow
Akero Therapeutics Inc. logo

In Akero Therapeutics' Phase 2b HARMONY Study, Both the 50mg and 28mg EFX Doses Achieved Statistical Significance on Primary and Secondary Histology Endpoints after 24 Weeks

ByQuantisnow·Wall Street's wire, on your screen.
AKRO· Akero Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track AKRO (Akero Therapeutics Inc.) and more on Quantisnow.